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osting by EAbstract A simple, sensitive and accurate spectrophotometric method has been described for
the assay of diphenhydramine hydrochloride (DPH) in raw material and in biological samples.
The method is based on extraction of DPH into dichloromethane as ion-pair complexes with patent
blue (PB), eriochrome black T (EBT), methyl orange (MO) and bromocresol purple (BCP) in acidic
medium. The coloured species exhibited absorption maxima at 632, 514, 428 and 414 nm for PB,
EBT, MO and BCP, with molar absorptivity values of 1.32 · 105, 2.36 · 104, 3.68 · 104 and
3.07 · 104 l mol1 cm1, respectively. The reaction conditions were optimized to obtain the maxi-
mum colour intensity. Beer’s law was obeyed with a good correlation coefﬁcient (0.9982–0.9993)
in the concentration ranges 0.5–3, 2.0–16, 2.0–10 and 1.0–10 lg ml1 for PB, EBT, MO and BCP
methods, respectively. The composition ratio of the ion-association complexes was found to be
1:1 in all cases as established by Job’s method. The conditional stability constant (Kf) and the free
energy changes (DG) were determined for all complexes formed. The proposed method was suc-
cessfully applied for the determination of DPH in tablets and human urine with good accuracy
and precision. Statistical comparison of the results with those obtained by the ofﬁcial method
showed good agreement and indicated no signiﬁcant difference in accuracy and precision.
ª 2010 King Saud University. All rights reserved..com (A.M. El-Didamony).
ity. All rights reserved. Peer-
d University.
lsevier1. Introduction
Diphenhydramine hydrochloride (DPH) (Scheme 1) 2-(diphe-
nylmethoxy)-N,N-dimethylethylamine hydrochloride) is an
effective antihistaminic and has been used for the treatment
of motion sickness and extra pyramidal symptoms, as well as
an antitussive and night-time sleep-aid. Recently, its use has
been reported, in combination with other drugs, as antiemetic
for the prevention of cisplatin-induced emesis in chemotherapy
treatment. It has also been used as sedative in dentistry for
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Scheme 1 Chemical structure of diphenhydramine HCl.
266 A.M. El-Didamony, M.A. Moustafachildren and in local anaesthesia (Goodman-Hillman et al.,
1996). Several methods have been proposed for determining
diphenhydramine hydrochloride in pharmaceutical prepara-
tions including capillary electrophoresis (Gomez et al., 2002;
Marchesini et al., 2003; Dong et al., 2005), atomic absorption
(Nerin et al., 1993; El Ries and Khalil, 2001), ﬂuorometry (Ala-
tayud et al., 1992; Reguera et al., 2004), ﬂow injection analysis
(Tipparat et al., 2002), spectrophotometry (Caddy et al., 1975;
Shamsa and Maghssoudi, 1976; Maghssoudi et al., 1977; El-
Shahat et al., 1992; Basavaiah and Charan, 2002). Chromato-
graphic methods have been used such as gas chromatography
(Raj et al., 1998), liquid chromatography (Kumar et al., 1998;
Marti´nez-Algaba et al., 2006) and high performance liquid
chromatography (HPLC) (Yuan and Locke, 1991; Ye and
Stewart, 1996; Muller and Sherma, 1999). The drug and its for-
mulations are ofﬁcial in BP (United States Pharmacopoeia,
2000), which recommended HPLC for its assay.
The aim of this study was to develop an accurate, reproduc-
ible and adequately sensitive extractive spectrophotometric
method based on the formation of dichloromethane soluble
ion-association complexes between DPH with patent blue
(PB), eriochrome black T (EBT), methyl orange (MO) and
bromocresol purple (BCP) in acidic medium. The selectivity
of the proposed method was studied and the results showed
that most of coexistent substances did not interfere in the
determination of DPH. The proposed method was applied
for determining DPH in bulk, tablets, and urine samples with
satisfactory results.
2. Experimental
2.1. Apparatus
All the absorbance spectral measurements were made using
spectroscan 80 D double-beam UV/visible spectrophotometerTable 1 Optical characteristics and statistical data of the regression
Parameters DPH–PB
kmax (nm) 632
pH 3.6
Molar absorptivity (l mol1 cm1) 1.32 · 105
Sandell’s sensitivity (ng cm2) 2.211
Beer’s limit (lg ml1) 0.5–3.0
Sy/x 0.0286
Slope (b) 0.4295
Intercept (a) 0.0317
SD of slope 0.0181
SD of intercept 0.0608
Correlation coeﬃcient (r) 0.9991
Stability constant (Kf) 4.974
Free energy change, DG (kJ mol1) 6.784(Biotech Engineering Ltd., UK), with wavelength range 190–
1100 nm, spectral bandwidth 2.0 nm, with 10 mm matched
quartz cells.
2.2. Reagents and solutions
All of the chemicals used were of analytical or pharmaceutical
grade and used without further puriﬁcation. Double distilled
water was used to prepare all solutions.
(i) Stock solutions of pure diphenhydramine hydrochloride
(DPH) were prepared by dissolving 20 mg of DPH with
distilled water in a 100 ml calibrated ﬂask. Working
solutions of lower concentrations (100 and 50 lg ml1)
were freshly prepared by appropriate dilution with
water.
(ii) A solutions of 5 · 104 M patent blue (PB), eriochrome
black T (EBT), methyl orange (MO) and bromocresol
purple (BCP) (Aldrich product) were prepared by dis-
solving an accurately weighted amount of the dyes in
distilled water and then diluted to the mark with water
in a 100 ml calibrated ﬂasks separately.
(iii) A series of buffer solutions of KCl–HCl (pH 1.0–2.2);
NaOAc–HCl (pH 3.0–5.2); NaOAc–AcOH (pH 3.42–
5.89); NaH2PO4–Na2HPO4 (pH 6.0–8.0) and potassium
hydrogen phthalate–NaOH (pH 4–5.6) were prepared
by following the standard methods (Britton, 1952).2.3. General recommended procedures
2.3.1. Procedure for calibration curve
Aliquots of DPH in the concentration range stated in Table 1,
were transferred into a series of 50 ml separating funnels. A
2.5 ml of 5 · 104 M dye solution and 2.0 ml of buffer solutions
of (pH 3.6, pH 5.0, or pH 4, or pH 4.6) were placed. The vol-
ume of the aqueous phase was adjusted to 10 ml with distilled
water and mixed well. The funnels were shaken vigorously with
10 ml of dichloromethane for 2 min. The two phases were al-
lowed to stand for clear separation and the dichloromethane
layer was dried by running through anhydrous sodium sulfate.
The absorbance of the organic phase was measured at 632, 514,
428 and 414 nm for PB, EBT, MO and BCP, respectively,
against dichloromethane. The calibration graphs are linear
over the concentration ranges and are given in Table 1.equations for the DPH reaction with PB, EBT, MO and BCP.
DPH–EBT DPH–MO DPH–BCP
514 428 414
5.2 4.0 4.6
2.36 · 104 3.68 · 104 3.07 · 104
12.364 7.929 9.504
2.0–16 2.0–10 1.0–10
0.0129 0.0163 7.07 · 103
0.0542 0.1335 0.0977
0.3574 0.09 0.1099
2.03 · 103 5.16 · 103 2.23 · 103
0.0364 0.0923 0.0150
0.9982 0.9992 0.9993
3.985 4.181 4.309
5.434 5.701 5.876
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Job’s method of continuous variations was employed; 2 ·
104 M solution of PB and DPH, 5 · 104 M of EBT, MO,
BCP and DPH solution were used. A series of solutions were
prepared in which the total volume of drug and reagent was
kept at 1.8 ml. The reagents were mixed in various proportions
and completed to 10 ml of distilled water, following the above-
mentioned procedure.0
0.2
0.4
350 400 450 500 550 600 650 700
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Figure 1 Absorption spectra of 3 lg ml1 of DPH–PB complex,
9 lg ml1 of DPH with EBT, MO and BCP complex against
dichloromethane as blank.2.3.3. Procedure for the assay of tablets
Ten tablets were weighed and powdered. A portion of the pow-
der equivalent to 20 mg of DPH was weighed and dissolved in
distilled water, ﬁltered into a 100 ml calibrated ﬂask to remove
the insoluble matter and diluted to volume with water. Solu-
tions of working range concentration were prepared by proper
dilution of this stock solution with water and followed the
above procedure for the analysis.2.3.4. Procedure for the assay of urine samples
The proposed method was applied to the determination of
DPH in human urine collected from six normal people and
transferred into well-cleaned sample tubes. Human urine
was 50-fold diluted with distilled water. For the determina-
tion of DPH in urine, 1.0 ml of diluted urine was put in a
50 ml separating funnel. The solution was prepared and then,
absorbance was measured following the same procedure as
that for standard solutions. The absolute recovery was deter-
mined for DPH by comparing the representative absorbance
of the treated urine with the absorbance of the standard
drug at the same concentration.3. Results and discussion
Extractive spectrophotometric procedures due to their sensitiv-
ity are widely used in the assay of drugs and hence, ion-pair
extractive spectrophotometry has received a considerable
attention for the quantitative determination of many pharma-
ceutical compounds (El-Didamony, 2005; Patel et al., 2007; El-
Didamony, 2008; Manjunatha et al., 2009; Issa et al., 2010; Ca-
g˘lar and O¨nal, 2010).0.8
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e3.1. Optimization of the reaction conditions
The course of the formation and extraction of the coloured
compounds of DPH with PB, EBT, MO and BCP depends
on the acidity of the solutions, the reagents concentrations
and on the nature of organic solvent used. These factors were
established by a number of preliminary experiments.0
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Figure 2 Effect of pH on the absorbance of ion-pair complexes of
PB with 3 lg ml1 DPH and EBT, MO and BCP with 9 lg ml1
DPH.3.1.1. Absorption spectra
Anionic dyes such as patent blue (PB), eriochrome black T
(EBT), methyl orange (MO) and bromocresol purple (BCP)
form ion-association complexes in acidic buffer solution with
the positively charged drug and these complexes are quantita-
tively extracted into dichloromethane. Absorption spectra of
the ion-pair complexes extracted into dichloromethane show
a maximum at 632, 514, 428 and 414 nm for BP, EBT, MO
and BCP, respectively, as shown in Fig. 1. The reagent blank
under similar conditions showed no absorption.3.1.2. Effect of pH and buffer media
It was observed that effective extraction for the complexes
depends on the type of buffer used and its pH. The effect of
buffer solution was studied by extracting the coloured com-
plexes in the presence of various buffers, such as KCl–HCl
(1.0–2.2), NaOAc–AcOH (3.0–6.0), potassium hydrogen
phthalate–NaOH (4.1–5.9) and NaOAc–HCl (7.0–9.0). The
experiments showed that the maximum colour intensity and
constant absorbance were observed in NaOAc–AcOH for
PB, MO and BCP. For EBT reagent, phthalate buffer was
the buffer of choice, which did not interfere and gave the high-
est sensitivity. The results are shown in Fig. 2 and it is evident
that absorbance of the complexes with PB, EBT, MO and BCP
was found to be constant within the pH ranges 3.0–3.8, 5.0–
5.6, 3.0–4.2 and 4.0–5.0, respectively. Thus, all the absorbance
measurements were made at pH 3.6, 5.2, 4.0 and 4.6 with PB,
EBT, MO and BCP, respectively. The optimum amount of
buffer solution used to give constant absorbance was also stud-
ied and found to be 2.0 ml.
3.1.3. Selecting of the extracting solvents
Several water-immiscible organic solvents, including benzene,
toluene, carbon tetrachloride, chloroform and dichlorometh-
ane were investigated. Dichloromethane was selected because
268 A.M. El-Didamony, M.A. Moustafaof its slightly higher efﬁciency on colour intensity and the
shortest time to reach the equilibrium between both phases.
3.1.4. Sequence of addition
From the experiment, we can see that when the addition se-
quence was dye–buffer–drug, the absorbance was the highest.
When the addition sequence was drug–dye–buffer, the absor-
bance was less.
3.1.5. Effect of time and temperature
The effect of time on the formation and stability of the ion-
association complexes was studied by measuring the absor-
bance’s of the extracted ion-association complexes at increas-
ing time intervals. At the beginning, the absorbance increased
gradually along with the time. After 10 min it achieved stability
and remained basically unaltered for more than 3 h.
The effect of temperature on the absorbance was also,
examined in the range of 30–100 C. The results showed that
the ion-association complexes were performed almost instanta-
neously in all cases at room temperature (25 ± 2 C) and the
inﬂuence of temperature was little. So, the absorbance was
measured at room temperature (25 ± 2 C).
3.1.6. Effect of dye concentration
The effect of the dye concentration on the intensity of the col-
our developed at selected wavelengths was tested using differ-
ent milliliters of 5 · 104 M of the reagents. It is apparent from
Fig. 3, that the maximum absorbance in each case, was found
with 2.0 ml of dyestuff, beyond which absorbance was con-
stant. Thus 2.5 ml of each dyestuff was used for ion-pair com-
plex formation throughout the experiment.
3.1.7. Stoichiometric ratio of the ion-association complex
The stoichiometry of the ion-association complex formed by
electrostatic attraction between positive protonated drug
(DPH+) and the anion of bromocresol purple (BCP) (as a
model example of the used dyes) was investigated by applying
the continuous variation method (Job, 1928; Vosburgh and0
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Figure 3 Effect of 5 · 104 M dye on the absorbance of ion-pair
complexes of: PB with 3.0 lg ml1 of DPH, EBT, MO and BCP
with 9.0 lg ml1 of DPH.Cooper, 1941) at the wavelength of maximum absorbance.
The results obtained showed that the stoichiometric ratio of
the ion-association complex is 1:1 (drug:dye) in all cases
(Fig. 4). The suggested mechanism of DPH+–BCP ion-pair
complex formation is described in Scheme 2. The extraction
equilibrium can be represented as follows:
DPHþaq: þDaq: $ DPHþDaq: $ DPHþDorg:3.1.8. Conditional stability constants (Kf) of ion-pair complexes
The conditional stability constants (Kf) of the ion-pair associ-
ates for DPH under the experimental conditions described
above were calculated from the continuous variation data
using the following equation (Inczedy, 1976):
Kf ¼ A=Am½1 A=Amnþ1CnD
ðnÞn
where A and Am are the observed maximum absorbance and
the absorbance value of the drug present is associated, respec-
tively. CD is the molar concentration of drug at the maximum
and n is the stoichiometric constant with which dye ion associ-
ates with drug. In accordance with the formula, the condi-
tional stability constants were found to be 4.974, 3.985,
4.181 and 4.309 for PB, EBT, MO and BCP, respectively.
The standard free energy change (DG) was related to the
association constant and calculated by the following equation
(Martin et al., 1969):
DG ¼ 2:303RT logKf
where (DG) is the free energy change of the complex
(kJ mol1), R the gas constant (1.987 cal mol1 deg1), T is
the temperature in kelvin (273+ C), and Kf is the association
constant of drug–reagent ion-pair complexes (l mol1).
3.1.9. Speciﬁcity and effect of excipients
Formation of the ion-pair complex with anionic dyes needs a
basic drug; therefore, no possible interference is expected from
other co-formulated drugs lacking any basic center. A system-0
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Figure 4 Continuous-variations study of drug–dye systems:
DPH–PB (2.0 · 104 M); DPH–EBT; DPH–MO and BCP–DPH
(5.0 · 104 M) ion-pair complexes.
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Scheme 2 Probable mechanism for the formation of 1:1 DPH–BCP.
Spectrophotometric determination of diphenhydramine hydrochloride 269atic study of the effect of excipients was performed, following
the proposed procedures for a 10-ml sample system, by adding
a known amount of excipients to the ﬁxed DPH concentration
(3.0 lg ml1). The results revealed the fact that no signiﬁcant
interference was observed from the excipients, such as glucose,
fructose, sucrose, lactose and starch commonly present in
pharmaceutical formulations. However, the drug content from
the powdered tablets was extracted into methylene chloride,
which completely eliminates the common excipients found in
drug formulations.
3.2. Validation of the proposed methods
3.2.1. Conformity to Beer’s law
Beer’s law is obeyed in the concentration (C, lg ml1) range of
0.5–3.0 lg ml1 with PB, 2.0–16 lg ml1 with EBT, 2.0–10
lg ml1 with MO and 1.0–10 lg ml1 with BCP. The molar
absorptivity (e) calculated and found to be 1.32 · 105, 2.36 ·
104, 3.68 · 104 and 3.07 · 104 l mol1 cm1, for PB, EBT, MO
andBCP, respectively, indicating high sensitivity of the reagents
under investigations for the determination of the cited drug.
The optical characteristics such as Beer’s law limits, corre-
lation coefﬁcient (r) and Sandell’s sensitivities (Sandell, 1950)
are recorded in Table 1. The regression analysis using the
method of least square was made for the slope (b), intercept
(a) and standard deviation of the residuals (Sy/x) obtainedTable 2 Evaluation of the accuracy and precision of the proposed
Method Added (lg ml1) Recovery (%) Precisio
DPH–PB 1 100.1 1.565
1.5 100.06 1.819
2 99.74 2.289
2.5 100.02 0.532
DPH–EBT 2 99.98 1.649
6 100.6 1.886
10 100.04 0.3019
14 100.02 0.4206
DPH–MO 3 99.82 1.646
5 99.88 1.743
7 100 0.7904
9 99.94 1.324
DPH–BCP 2 100.12 3.277
4 100.14 1.785
6 99.96 1.094
8 99.90 0.9942
a Mean of ﬁve determinations.
b Percentage relative error.
c Conﬁdence limit at 95% conﬁdence level and ﬁve degrees of freedomfrom different concentrations are given in Table 1. The inter-
cept of the lines were very small indicating that there is no sys-
tematic difference between determined and expected
concentration within the investigated range using the proposed
method.
3.2.2. Precision and accuracy
In order to determine the accuracy and precision of the
proposed method, solution containing four different concen-
trations of DPH were prepared and ﬁve replicates determina-
tions, covering the usable concentration range, were carried
out for the pure form and the pharmaceutical preparation of
the drug under investigation. The analytical results obtained
for this investigation are summarized in Table 2. The low val-
ues of percent relative standard deviation (RSD%) indicate
good precision and reproducibility of the proposed method.
The average percent recoveries obtained were quantitative
(99.85–100.6), indicating good accuracy of the method. The
mean values obtained and the calculated standard deviations
are compared with those obtained by the pharmacopoeia
method of DPH (United States Pharmacopoeia, 2000) by
applying the t- and F-tests (Table 3). Such comparison showed
that there is no signiﬁcant difference, at 95% conﬁdence level,
between the mean values or variances obtained by the pro-
posed and the pharmacopoeia method. This indicates the high
accuracy and precision of the present method.method for DPH determination.
n, RSDa (%) Accuracy, Erb (%) Conﬁdence limitc
0.1 1.001 ± 8.97 · 103
0.0667 1.501 ± 0.0142
0.3 1.994 ± 0.0224
0.04 2.501 ± 6.81 · 103
0.05 1.999 ± 5.62 · 103
0.6 6.036 ± 0.0127
0.0214 10.004 ± 3.77 · 103
0.04 14.003 ± 5.39 · 103
0.2 2.994 ± 5.58 · 103
0.12 4.994 ± 0.0112
0.00 7 ± 7.15 · 103
0.0667 8.994 ± 0.0164
0.1 2.002 ± 0.0116
0.125 4.005 ± 0.0106
0.05 5.997 ± 9.67 · 103
0.1 7.992 ± 0.0101
.
Table 3 Application of the proposed spectrophotometric method to the determination of DPH in tablets and urine.
Method Taken (lg ml1) Samples Oﬃcial method
Sultan Urine
DPH–PB 1.5 101.02 ± 0.0202 100.93 ± 0.0126 99.98 ± 0.0169
F= 1.4286 F= 1.7990
t= 0.8771 t= 1.4241
DPH–EBT 8.0 99.98 ± 0.0269 99.98 ± 0.0185 99.95 ± 0.0203
F= 1.7559 F= 1.2041
t= 0.4457 t= 0.7303
DPH–MO 3.0 99.88 ± 0.0102 99.86 ± 0.0134 99.92 ± 0.0115
F= 1.2711 F= 1.3577
t= 1.6265 t= 1.1331
DPH–BCP 6.0 100.12 ± 0.0290 99.98 ± 0.0120 100.05 ± 0.0217
F= 1.7859 F= 3.2700
t= 0.9671 t= 1.2108
270 A.M. El-Didamony, M.A. Moustafa3.2.3. Analytical application
The validity of the proposed method for the analysis of DPH
in tablets and urine was examined by analyzing the sample
using the proposed method.
3.2.4. Determination of DPH in tablets and urine
The proposed method has been successfully applied to the
determination of DPH in commercial tablets purchased locally
and urine samples. The results are shown in Table 3. The mean
percent recovery obtained from ﬁve replicate measurements of
tablets and urine containing DPH were 99.86–101.02% (Table
3) and indicate that the proposed method was effective for the
determination of DPH in tablets and urine samples. The calcu-
lated Student’s t-values and F-values did not exceed the theo-
retical ones at 95% conﬁdence level. Therefore, there is no
signiﬁcant difference between the proposed method and ofﬁ-
cial method (United States Pharmacopoeia, 2000).
4. Conclusion
The reagents utilized in the proposed method are cheaper,
readily available and the proposed method does not involve
any critical reaction conditions or tedious sample preparation.
The method is unaffected by slight variations in the experimen-
tal conditions, such as pH, reagent concentration or tempera-
ture. The proposed method is sufﬁciently sensitive to permit
determination even down to 0.5 lg ml1. The sensitivity in
term of molar absorptivity and the precision in term of RSD
of the method are very suitable for the determination of
DPH in tablets and biological ﬂuids. Moreover, the methods
are free from interference by common additives and excipients.
The comparative study of the molar absorptivity indicated
good sensitivity of the proposed method which follow the or-
der of PB >MO> BCP> EBT.
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